Erratum: Comparative effectiveness of antiviral treatment for hepatitis B: A systematic review and Bayesian network meta-analysis (European Journal of Gastroenterology and Hepatology (2015) 27 (882-894) DOI: 10.1097/MEG.0000000000000376);Comparative effectiveness of antiviral treatment for hepatitis B: A systematic review and Bayesian network meta-analysis

European Journal of Gastroenterology and Hepatology

Volumn 27, Issue 8, 2015, Pages 882-894

  Govan, Lindsay ^a   Wu, Olivia ^a   Xin, Yiqiao ^a   Hutchinson, Sharon J ^b   Hawkins, Neil ^c  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^c ICON PLC   (United Kingdom)

Author keywords

HBeAg negative; HBeAg positive; indirect comparisons; mixed treatment comparisons; surrogate outcomes

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON; PLACEBO; TELBIVUDINE; TENOFOVIR; ANTIVIRUS AGENT; BIOLOGICAL MARKER; VIRUS DNA;

BAYESIAN LEARNING; COMPARATIVE EFFECTIVENESS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MONOTHERAPY; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; BAYES THEOREM; BLOOD; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFECTS; ECONOMICS; GENETICS; HEPATITIS B, CHRONIC; IMMUNOLOGY; MARKOV CHAIN; META ANALYSIS; MONTE CARLO METHOD; ODDS RATIO; TIME FACTOR; TREATMENT OUTCOME; VIRUS LOAD;

ANTIVIRAL AGENTS; BAYES THEOREM; BIOMARKERS; COST-BENEFIT ANALYSIS; DNA, VIRAL; DRUG COSTS; DRUG THERAPY, COMBINATION; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MARKOV CHAINS; MONTE CARLO METHOD; ODDS RATIO; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84938492046     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000920     Document Type: Erratum

References (57)

1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012; 30:2212-2219.
2. World Health Organisation. Hepatitis B. Fact Sheet No. 204 (updated July 2013). 2013. http://www.who.int/mediacentre/factsheets/fs204/ en/. [Accessed November 2014].
3. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2095-2128.
4. National Institute for Health and Care Excellence. Diagnosis and management of chronic hepatitis B in children, young people and adults. UK: NICE clinical guideline; 2013.
5. Woo G, Tomlinson G, Nishikawa Y, Kowgier M, Sherman M, Wong DK, et al. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139:1218-1229.
6. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23:3105-3124.
7. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med 2002; 21:2313-2324.
8. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res 2001; 10:277-303.
9. Mills EJ, Thorlund K, Ioannidis JP. Demystifying trial networks and network meta-analysis. BMJ 2013; 346:f2914.
10. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005; 331:897-900.
11. Salanti G, Higgins JP, Ades AE, Ioannidis JP. Evaluation of networks of randomized trials. Stat Methods Med Res 2008; 17:279-301.
12. Lambert PC, Sutton AJ, Burton PR, Abrams KR, Jones DR. How vague is vague A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGS. Stat Med 2005; 24:2401-2428.
13. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WinBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000; 10:325-337.
14. Piccolo P, Lenci I, Demelia L, Bandiera F, Piras MR, Antonucci G, et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2009; 14:1165-1174.
15. Lok AS, Trinh H, Carosi G, Akarca US, Gadano A, Habersetzer F, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology 2012; 143:619-628.
16. Chan HL, Leung NW, Hui AY, Wong VW, Liew CT, Chim AM, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142:240-250.
17. Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, et al. 018 Study Group. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007; 147:745-754.
18. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. BEHoLD AI463022 Study Group. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354:1001-1010.
19. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256-1263.
20. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003; 348: 800-807.
21. Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trial. Hepatology 2008; 47:447-454.
22. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, et al. HBV 99-01 Study Group; Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365:123-129.
23. Kaymakoglu S, Oguz D, Gur G, Gurel S, Tankurt E, Ersöz G, et al. Pegylated interferon alfa-2b monotherapy and pegylated interferon alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B. Antimicrob Agents Chemother 2007; 51:3020-3022.
24. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl JMed 1998; 339:61-68.
25. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, et al. Telbivudine Phase II Investigator Group. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129:528-536.
26. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. BEHoLD AI463027 Study Group. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006; 354:1011-1020.
27. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, et al. Globe Study Group. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357:2576-2588.
28. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAgpositive chronic hepatitis B. N Engl J Med 2005; 352:2682-2695.
29. Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology 2009; 49:72-79.
30. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808-816.
31. Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206-1217.
32. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359:2442-2455.
33. Papadopoulos VP, Chrysagis DN, Protopapas AN, Goulis IG, Dimitriadis GT, Mimidis KP. Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HBeAg-negative chronic hepatitis B: a randomised study. Med Sci Monit 2009; 15:CR56-CR61.
34. Ren FY, Piao DM, Piao XX. A one-year trial of entecavir treatment in patients with HBeAg-positive chronic hepatitis B. World J Gastroenterol 2007; 13:4264-4267.
35. Sung JJ, Lai JY, Zeuzem S, Chow WC, Heathcote EJ, Perrillo RP, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008; 48:728-735.
36. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57:167-185.
37. Spearman CW, Sonderup MW, Botha JF, van der Merwe SW, Song E, Kassianides C, et al. Division of Hepatology, Department of Medicine, University of Cape Town, South Africa. South African guideline for the management of chronic hepatitis B: 2013. S Afr Med J 2013; 103 (Pt 2):337-349.
38. World Health Organisation. Global policy report on the prevention and control of viral hepatitis in WHO Member States. Geneva: World Health Organisation; 2013.
39. Wong GL, Chan HL. Predictors of treatment response in chronic hepatitis B. Drugs 2009; 69:2167-2177.
40. Andersson KL, Chung RT. Monitoring during and after antiviral therapy for hepatitis B. Hepatology 2009; 49 (Suppl):S166-S173.
41. Fattovich G, Bortolotti F, Donato F. Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors. J Hepatol 2008; 48:335-352.
42. Feld JJ, Wong DK, Heathcote EJ. Endpoints of therapy in chronic hepatitis B. Hepatology 2009; 49 (Suppl):S96-S102.
43. Hui CK, Leung N, Shek TW, Yao H, Lee WK, Lai JY, et al. Hong Kong Liver Fibrosis Study Group. Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology 2007; 46:690-698.
44. Wong VW, Sung JJ. Antiviral therapy for chronic hepatitis B: are we doing any good to patients? J Antimicrob Chemother 2009; 64:223-226.
45. Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis. Stat Med 1996; 15:2733-2749.
46. Friedrich JO, Adhikari NK, Beyene J. Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data. BMC Med Res Methodol 2007; 7:5.
47. Donegan S, Williamson P, Gamble C, Tudur-Smith C. Indirect comparisons: a review of reporting and methodological quality. PLoS One 2010; 5:e11054.
48. Glenny AM, Altman DG, Song F, Sakarovitch C, Deeks JJ, D'Amico R, et al. International Stroke Trial Collaborative Group. Indirect comparisons of competing interventions. Health Technol Assess 2005; 9:1-134.
49. Li T, Puhan MA, Vedula SS, Singh S, Dickersin K. Network metaanalysis-highly attractive but more methodological research is needed. BMC Med 2011; 9:79.
50. Caldwell DM, Welton NJ, Ades AE. Mixed treatment comparison analysis provides internally coherent treatment effect estimates based on overviews of reviews and can reveal inconsistency. J Clin Epidemiol 2010; 63: 875-882.
51. Dias S, Welton NJ, Caldwell DM, Ades AE. Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010; 29:932-944.
52. Jansen JP, Fleurence R, Devine B, Itzler R, Barrett A, Hawkins N, et al. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011; 14:417-428.
53. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC, et al. Conducting indirect-treatment-comparison and network-metaanalysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health 2011; 14:429-437.
54. Brown RS Jr. Long-term data on current treatments for chronic hepatitis B. Gastroenterol Hepatol 2011; 7:6-7.
55. Holt A. Recent advances in the management of viral hepatitis. J R Coll Physicians Edinb 2011; 41:59-66.
56. Lin CL, Kao JH. Recent advances in the treatment of chronic hepatitis B. Expert Opin Pharmacother 2011; 12:2025-2040.
57. Messori A, Del Santo F, Maratea D, Trippoli S. Single-drug treatments for chronic hepatitis B: summarising current information by network meta-analysis. Aliment Pharmacol Ther 2011; 34:105-107.